Bavarian Nordic - Asset Resilience Ratio
Bavarian Nordic (BAVA) has an Asset Resilience Ratio of 10.83% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See BAVA working capital efficiency to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2000–2025)
This chart shows how Bavarian Nordic's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see BAVA total assets.
Liquid Assets Composition Over Time
This chart breaks down Bavarian Nordic's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore Bavarian Nordic (BAVA) long-term investment share to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Dkr0.00 | 0% |
| Short-term Investments | Dkr1.62 Billion | 10.83% |
| Total Liquid Assets | Dkr1.62 Billion | 10.83% |
Asset Resilience Insights
- Moderate Liquidity: Bavarian Nordic has 10.83% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
Bavarian Nordic Industry Peers by Asset Resilience Ratio
Compare Bavarian Nordic's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 15.95% |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH |
Biotechnology | 33.23% |
|
Nanobiotix
NASDAQ:NBTX |
Biotechnology | 4.71% |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253 |
Biotechnology | 65.12% |
Annual Asset Resilience Ratio for Bavarian Nordic (2000–2025)
The table below shows the annual Asset Resilience Ratio data for Bavarian Nordic.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 10.83% | Dkr1.62 Billion ≈ $253.30 Million |
Dkr14.95 Billion ≈ $2.34 Billion |
+7.00pp |
| 2024-12-31 | 3.83% | Dkr551.54 Million ≈ $86.29 Million |
Dkr14.41 Billion ≈ $2.25 Billion |
+1.11pp |
| 2023-12-31 | 2.72% | Dkr390.25 Million ≈ $61.06 Million |
Dkr14.35 Billion ≈ $2.25 Billion |
-15.60pp |
| 2022-12-31 | 18.32% | Dkr2.27 Billion ≈ $355.12 Million |
Dkr12.39 Billion ≈ $1.94 Billion |
-7.53pp |
| 2021-12-31 | 25.85% | Dkr3.12 Billion ≈ $488.90 Million |
Dkr12.09 Billion ≈ $1.89 Billion |
+10.05pp |
| 2020-12-31 | 15.80% | Dkr1.38 Billion ≈ $216.56 Million |
Dkr8.76 Billion ≈ $1.37 Billion |
+13.32pp |
| 2019-12-31 | 2.48% | Dkr174.82 Million ≈ $27.35 Million |
Dkr7.05 Billion ≈ $1.10 Billion |
-64.51pp |
| 2018-12-31 | 66.99% | Dkr2.05 Billion ≈ $320.82 Million |
Dkr3.06 Billion ≈ $478.91 Million |
-6.34pp |
| 2017-12-31 | 73.33% | Dkr2.31 Billion ≈ $361.72 Million |
Dkr3.15 Billion ≈ $493.26 Million |
+35.75pp |
| 2016-12-31 | 37.58% | Dkr1.06 Billion ≈ $166.04 Million |
Dkr2.82 Billion ≈ $441.79 Million |
+2.76pp |
| 2015-12-31 | 34.82% | Dkr692.72 Million ≈ $108.38 Million |
Dkr1.99 Billion ≈ $311.23 Million |
+4.02pp |
| 2014-12-31 | 30.80% | Dkr581.35 Million ≈ $90.96 Million |
Dkr1.89 Billion ≈ $295.28 Million |
+18.05pp |
| 2013-12-31 | 12.76% | Dkr185.28 Million ≈ $28.99 Million |
Dkr1.45 Billion ≈ $227.21 Million |
+0.00pp |
| 2012-12-31 | 12.76% | Dkr196.36 Million ≈ $30.72 Million |
Dkr1.54 Billion ≈ $240.82 Million |
-3.02pp |
| 2011-12-31 | 15.78% | Dkr311.92 Million ≈ $48.80 Million |
Dkr1.98 Billion ≈ $309.25 Million |
+9.72pp |
| 2010-12-31 | 6.06% | Dkr88.87 Million ≈ $13.90 Million |
Dkr1.47 Billion ≈ $229.54 Million |
-2.13pp |
| 2009-12-31 | 8.19% | Dkr104.05 Million ≈ $16.28 Million |
Dkr1.27 Billion ≈ $198.87 Million |
-13.86pp |
| 2008-12-31 | 22.05% | Dkr373.54 Million ≈ $58.44 Million |
Dkr1.69 Billion ≈ $265.08 Million |
+9.07pp |
| 2007-12-31 | 12.98% | Dkr224.80 Million ≈ $35.17 Million |
Dkr1.73 Billion ≈ $270.99 Million |
-11.26pp |
| 2006-12-31 | 24.24% | Dkr231.32 Million ≈ $36.19 Million |
Dkr954.42 Million ≈ $149.33 Million |
+12.01pp |
| 2005-12-31 | 12.23% | Dkr113.52 Million ≈ $17.76 Million |
Dkr928.56 Million ≈ $145.28 Million |
-6.47pp |
| 2004-12-31 | 18.70% | Dkr112.57 Million ≈ $17.61 Million |
Dkr602.10 Million ≈ $94.20 Million |
-1.98pp |
| 2003-12-31 | 20.68% | Dkr88.76 Million ≈ $13.89 Million |
Dkr429.17 Million ≈ $67.15 Million |
+15.95pp |
| 2002-12-31 | 4.74% | Dkr15.04 Million ≈ $2.35 Million |
Dkr317.70 Million ≈ $49.71 Million |
-28.91pp |
| 2001-12-31 | 33.65% | Dkr20.82 Million ≈ $3.26 Million |
Dkr61.87 Million ≈ $9.68 Million |
-4.56pp |
| 2000-12-31 | 38.21% | Dkr31.98 Million ≈ $5.00 Million |
Dkr83.69 Million ≈ $13.09 Million |
-- |
About Bavarian Nordic
Bavarian Nordic A/S develops, manufactures, and supplies life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; Vaxchora, an oral vaccine for immunization against cholera; and Vivotif/Typhoral, an or… Read more